Alvaro Yanez Touzet

Alvaro Yanez Touzet

Auto-generated profile, based on publicly available information

Alvaro Yanez Touzet

Department of Neurosurgery, King's College Hospital, London, UK; Department of Basic and Clinical Neurosciences, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, London, UK; School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
ATAlvaro Yanez Touzet
Alvaro Yanez Touzet
ABAniqah Bhatti
Aniqah Bhatti
EDEsmee Dohle
Esmee Dohle
FBFaheem Bhatti
Faheem Bhatti
Keng Siang LeeKeng Siang Lee
Keng Siang Lee
BDBenjamin Davies
Benjamin Davies
Objectives To evaluate the measurement properties of outcome measures currently used in the assessment of degenerative cervical myelopathy (DCM) for clinical research. Design Systematic review Data sources MEDLINE and EMBASE were searched through 4 August 2020. Eligibility criteria Primary clinical research published in English and whose primary purpose was to evaluate the measurement properties or clinically important differences of instruments used in DCM. Data extraction and synthesis Psychometric properties and clinically important differences were both extracted from each study, assessed for risk of bias and presented in accordance with the Consensus-based Standards for the selection of health Measurement Instruments criteria. Results Twenty-nine outcome instruments were identified from 52 studies published between 1999 and 2020. They measured neuromuscular function (16 instruments), life impact (five instruments), pain (five instruments) and radiological scoring (five instruments). No instrument had evaluations for all 10 measurement properties and <50% had assessments for all three domains (ie, reliability, validity and responsiveness). There was a paucity of high-quality evidence. Notably, there were no studies that reported on structural validity and no high-quality evidence that discussed content validity. In this context, we identified nine instruments that are interpretable by clinicians: the arm and neck pain scores; the 12-item and 36-item short form health surveys; the Japanese Orthopaedic Association (JOA) score, modified JOA and JOA Cervical Myelopathy Evaluation Questionnaire; the neck disability index; and the visual analogue scale for pain. These include six scores with barriers to application and one score with insufficient criterion and construct validity. Conclusions This review aggregates studies evaluating outcome measures used to assess patients with DCM. Overall, there is a need for a set of agreed tools to measure outcomes in DCM. These findings will be used to inform the development of a core measurement set as part of AO Spine RECODE-DCM.

31 December 2021 in Global Spine Journal
Verified
Journal Article
Open access
PDF file
LTLindsay Tetreault
Lindsay Tetreault
PGPhilip Garwood
Philip Garwood
AGAref-Ali Gharooni
Aref-Ali Gharooni
ATAlvaro Yanez Touzet
Alvaro Yanez Touzet
LNLaura Nanna-Lohkamp
Laura Nanna-Lohkamp
BDBenjamin Davies
Benjamin Davies
Study design: Narrative Review. Objective: To (i) discuss why assessment and monitoring of disease progression is critical in Degenerative cervical myelopathy (DCM); (ii) outline the important features of an ideal assessment tool and (iii) discuss current and novel strategies for detecting subtle deterioration in DCM. Methods: Literature review Results: Degenerative cervical myelopathy is an overarching term used to describe progressive injury to the cervical spinal cord by age-related changes of the spinal axis. Based on a study by Smith et al (2020), the prevalence of DCM is approximately 2.3% and is expected to rise as the global population ages. Given the global impact of this disease, it is essential to address important knowledge gaps and prioritize areas for future investigation. As part of the AO Spine RECODE-DCM (Research Objectives and Common Data Elements for Degenerative Cervical Myelopathy) project, a priority setting partnership was initiated to increase research efficiency by identifying the top ten research priorities for DCM. One of the top ten priorities for future DCM research was: What assessment tools can be used to evaluate functional impairment, disability and quality of life in people with DCM? What instruments, tools or methods can be used or developed to monitor people with DCM for disease progression or improvement either before or after surgical treatment? Conclusions: With the increasing prevalence of DCM, effective surveillance of this population will require both the implementation of a monitoring framework as well as the development of new assessment tools.

22 August 2024 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
BDBenjamin Davies
Benjamin Davies
Xiaoyu YangXiaoyu Yang
Xiaoyu Yang
DKDanyal Z. Khan
Danyal Z. Khan
OMOliver D. Mowforth
Oliver D. Mowforth
ATAlvaro Y. Touzet
Alvaro Y. Touzet
MKMark R.N. Kotter
Mark R.N. Kotter
Background: Degenerative cervical myelopathy (DCM) is a progressive chronic spinal cord injury estimated to affect 1 in 50 adults. Without standardised guidance, clinical research studies have selected outcomes at their discretion, often underrepresenting the disease and limiting comparability between studies. Utilising a standard minimum data set formed via multi-stakeholder consensus can address these issues. This combines processes to define a core outcome set (COS)—a list of key outcomes—and core data elements (CDEs), a list of key sampling characteristics required to interpret the outcomes. Further “how” these outcomes should be measured and/or reported is then defined in a core measurement set (CMS). This can include a recommendation of a standardised time point at which outcome data should be reported. This study defines a COS, CDE, and CMS for DCM research. Methods and findings: A minimum data set was developed using a series of modified Delphi processes. Phase 1 involved the setup of an international DCM stakeholder group. Phase 2 involved the development of a longlist of outcomes, data elements, and formation into domains. Phase 3 prioritised the outcomes and CDEs using a two-stage Delphi process. Phase 4 determined the final DCM minimal data set using a consensus meeting. Using the COS, Phase 5 finalised definitions of the measurement construct for each outcome. In Phase 6, a systematic review of the literature was performed, to scope and define the psychometric properties of measurement tools. Phase 7 used a modified Delphi process to inform the short-listing of candidate measurement tools. The final measurement set was then formed through a consensus meeting (Phase 8). To support implementation, the data set was then integrated into template clinical research forms (CRFs) for use in future clinical trials (Phase 9). In total, 28 outcomes and 6 domains (Pain, Neurological Function, Life Impact, Radiology, Economic Impact, and Adverse Events) were entered into the final COS. Thirty two outcomes and 4 domains (Individual, Disease, Investigation, and Intervention) were entered into the final CDE. Finally, 4 outcome instruments (mJOA, NDI, SF-36v2, and SAVES2) were identified for the CMS, with a recommendation for trials evaluating outcomes after surgery, to include baseline measurement and at 6 months from surgery. Conclusions: The AO Spine RECODE-DCM has produced a minimum data set for use in DCM clinical trials today. These are available at https://myelopathy.org/minimum-dataset/. While it is anticipated the CDE and COS have strong and durable relevance, it is acknowledged that new measurement tools, alongside an increasing transition to study patients not undergoing surgery, may necessitate updates and adaptation, particularly with respect to the CMS.

18 June 2024 in World Neurosurgery
Verified
Journal Article
Open access
GAGideon Adegboyega
Gideon Adegboyega
CGConor Gillespie
Conor Gillespie
MWMatthew Watson
Matthew Watson
Keng Siang LeeKeng Siang Lee
Keng Siang Lee
JBJamie Brannigan
Jamie Brannigan
PHPeter John Ashton Hutchinson
Peter John Ashton Hutchinson

9 June 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
BDBenjamin Davies
Benjamin Davies
ATAlvaro Yanez Touzet
Alvaro Yanez Touzet
OMOliver D Mowforth
Oliver D Mowforth
Keng Siang LeeKeng Siang Lee
Keng Siang Lee
DKDanyal Khan
Danyal Khan
MKMark R N Kotter
Mark R N Kotter
Introduction Progress in degenerative cervical myelopathy (DCM) is hindered by inconsistent measurement and reporting. This impedes data aggregation and outcome comparison across studies. This limitation can be reversed by developing a core measurement set (CMS) for DCM research. Previously, the AO Spine Research Objectives and Common Data Elements for DCM (AO Spine RECODE-DCM) defined ‘what’ should be measured in DCM: the next step of this initiative is to determine ‘how’ to measure these features. This protocol outlines the steps necessary for the development of a CMS for DCM research and audit. Methods and analysis The CMS will be developed in accordance with the guidance developed by the Core Outcome Measures in Effectiveness Trials and the Consensus-based Standards for the selection of health Measurement Instruments. The process involves five phases. In phase 1, the steering committee agreed on the constructs to be measured by sourcing consensus definitions from patients, professionals and the literature. In phases 2 and 3, systematic reviews were conducted to identify tools for each construct and aggregate their evidence. Constructs with and without tools were identified, and scoping reviews were conducted for constructs without tools. Evidence on measurement properties, as well as on timing of assessments, are currently being aggregated. These will be presented in phase 4: a consensus meeting where a multi-disciplinary panel of experts will select the instruments that will form the CMS. Following selection, guidance on the implementation of the CMS will be developed and disseminated (phase 5). A preliminary CMS review scheduled at 4 years from release. Ethics and dissemination Ethical approval was obtained from the University of Cambridge (HBREC2019.14). Dissemination strategies will include peer-reviewed scientific publications; conference presentations; podcasts; the identification of AO Spine RECODE-DCM ambassadors; and engagement with relevant journals, funders and the DCM community.

23 May 2018 in Advanced Biosystems
Verified
Journal Article
Closed access
PDF file
AYAlvaro Yanez
Alvaro Yanez
IDIsrael Desta
Israel Desta
PCPatrick Commins
Patrick Commins
MMMazin Magzoub
Mazin Magzoub
PNPanče Naumov
Panče Naumov